Partnership Supports Mydecine’s Drug Development & Clinical Trials Pipeline Provides Update on Debt Settlement *NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES DENVER, Feb. 24, 2021 (GLOBE NEWSWIRE) — Mydecine Innovations Group (CSE: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company’), an emerging biopharma and life sciences company…


Previous articleBeckley Psytech appoints ex-pharma CEO as Chief Operating Officer
Next articleEntheon Biomedical Corp. Provides Update on Subsidiary, HaluGen Life Sciences